Api Drug Development - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB510240828

Publication Date:

October 14, 2024

Pages:

115

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global market for Api Drug Development was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Api Drug Development, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Api Drug Development by region & country, by Type, and by Application.
The Api Drug Development market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Api Drug Development.
Market Segmentation
By Company
Almac
Patheon pharma services
Seqens
Malvern Panalytical
CordenPharma
Eurofins CDMO
API Corporation
Wavelength
Sterling
Drug Discovery Alliances
API Pharma tech
Biocon
Segment by Type:
Synthetic Type
Natural Type
Segment by Application
Pharmaceutical
Chemical Industry
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Api Drug Development manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Api Drug Development in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Api Drug Development in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Market Overview
1.1 Api Drug Development Product Introduction
1.2 Global Api Drug Development Market Size Forecast
1.3 Api Drug Development Market Trends & Drivers
1.3.1 Api Drug Development Industry Trends
1.3.2 Api Drug Development Market Drivers & Opportunity
1.3.3 Api Drug Development Market Challenges
1.3.4 Api Drug Development Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Api Drug Development Players Revenue Ranking (2023)
2.2 Global Api Drug Development Revenue by Company (2019-2024)
2.3 Key Companies Api Drug Development Manufacturing Base Distribution and Headquarters
2.4 Key Companies Api Drug Development Product Offered
2.5 Key Companies Time to Begin Mass Production of Api Drug Development
2.6 Api Drug Development Market Competitive Analysis
2.6.1 Api Drug Development Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Api Drug Development Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Api Drug Development as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Synthetic Type
3.1.2 Natural Type
3.2 Global Api Drug Development Sales Value by Type
3.2.1 Global Api Drug Development Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Api Drug Development Sales Value, by Type (2019-2030)
3.2.3 Global Api Drug Development Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Pharmaceutical
4.1.2 Chemical Industry
4.1.3 Other
4.2 Global Api Drug Development Sales Value by Application
4.2.1 Global Api Drug Development Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Api Drug Development Sales Value, by Application (2019-2030)
4.2.3 Global Api Drug Development Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Api Drug Development Sales Value by Region
5.1.1 Global Api Drug Development Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Api Drug Development Sales Value by Region (2019-2024)
5.1.3 Global Api Drug Development Sales Value by Region (2025-2030)
5.1.4 Global Api Drug Development Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Api Drug Development Sales Value, 2019-2030
5.2.2 North America Api Drug Development Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Api Drug Development Sales Value, 2019-2030
5.3.2 Europe Api Drug Development Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Api Drug Development Sales Value, 2019-2030
5.4.2 Asia Pacific Api Drug Development Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Api Drug Development Sales Value, 2019-2030
5.5.2 South America Api Drug Development Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Api Drug Development Sales Value, 2019-2030
5.6.2 Middle East & Africa Api Drug Development Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Api Drug Development Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Api Drug Development Sales Value
6.3 United States
6.3.1 United States Api Drug Development Sales Value, 2019-2030
6.3.2 United States Api Drug Development Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Api Drug Development Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Api Drug Development Sales Value, 2019-2030
6.4.2 Europe Api Drug Development Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Api Drug Development Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Api Drug Development Sales Value, 2019-2030
6.5.2 China Api Drug Development Sales Value by Type (%), 2023 VS 2030
6.5.3 China Api Drug Development Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Api Drug Development Sales Value, 2019-2030
6.6.2 Japan Api Drug Development Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Api Drug Development Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Api Drug Development Sales Value, 2019-2030
6.7.2 South Korea Api Drug Development Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Api Drug Development Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Api Drug Development Sales Value, 2019-2030
6.8.2 Southeast Asia Api Drug Development Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Api Drug Development Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Api Drug Development Sales Value, 2019-2030
6.9.2 India Api Drug Development Sales Value by Type (%), 2023 VS 2030
6.9.3 India Api Drug Development Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Almac
7.1.1 Almac Profile
7.1.2 Almac Main Business
7.1.3 Almac Api Drug Development Products, Services and Solutions
7.1.4 Almac Api Drug Development Revenue (US$ Million) & (2019-2024)
7.1.5 Almac Recent Developments
7.2 Patheon pharma services
7.2.1 Patheon pharma services Profile
7.2.2 Patheon pharma services Main Business
7.2.3 Patheon pharma services Api Drug Development Products, Services and Solutions
7.2.4 Patheon pharma services Api Drug Development Revenue (US$ Million) & (2019-2024)
7.2.5 Patheon pharma services Recent Developments
7.3 Seqens
7.3.1 Seqens Profile
7.3.2 Seqens Main Business
7.3.3 Seqens Api Drug Development Products, Services and Solutions
7.3.4 Seqens Api Drug Development Revenue (US$ Million) & (2019-2024)
7.3.5 Malvern Panalytical Recent Developments
7.4 Malvern Panalytical
7.4.1 Malvern Panalytical Profile
7.4.2 Malvern Panalytical Main Business
7.4.3 Malvern Panalytical Api Drug Development Products, Services and Solutions
7.4.4 Malvern Panalytical Api Drug Development Revenue (US$ Million) & (2019-2024)
7.4.5 Malvern Panalytical Recent Developments
7.5 CordenPharma
7.5.1 CordenPharma Profile
7.5.2 CordenPharma Main Business
7.5.3 CordenPharma Api Drug Development Products, Services and Solutions
7.5.4 CordenPharma Api Drug Development Revenue (US$ Million) & (2019-2024)
7.5.5 CordenPharma Recent Developments
7.6 Eurofins CDMO
7.6.1 Eurofins CDMO Profile
7.6.2 Eurofins CDMO Main Business
7.6.3 Eurofins CDMO Api Drug Development Products, Services and Solutions
7.6.4 Eurofins CDMO Api Drug Development Revenue (US$ Million) & (2019-2024)
7.6.5 Eurofins CDMO Recent Developments
7.7 API Corporation
7.7.1 API Corporation Profile
7.7.2 API Corporation Main Business
7.7.3 API Corporation Api Drug Development Products, Services and Solutions
7.7.4 API Corporation Api Drug Development Revenue (US$ Million) & (2019-2024)
7.7.5 API Corporation Recent Developments
7.8 Wavelength
7.8.1 Wavelength Profile
7.8.2 Wavelength Main Business
7.8.3 Wavelength Api Drug Development Products, Services and Solutions
7.8.4 Wavelength Api Drug Development Revenue (US$ Million) & (2019-2024)
7.8.5 Wavelength Recent Developments
7.9 Sterling
7.9.1 Sterling Profile
7.9.2 Sterling Main Business
7.9.3 Sterling Api Drug Development Products, Services and Solutions
7.9.4 Sterling Api Drug Development Revenue (US$ Million) & (2019-2024)
7.9.5 Sterling Recent Developments
7.10 Drug Discovery Alliances
7.10.1 Drug Discovery Alliances Profile
7.10.2 Drug Discovery Alliances Main Business
7.10.3 Drug Discovery Alliances Api Drug Development Products, Services and Solutions
7.10.4 Drug Discovery Alliances Api Drug Development Revenue (US$ Million) & (2019-2024)
7.10.5 Drug Discovery Alliances Recent Developments
7.11 API Pharma tech
7.11.1 API Pharma tech Profile
7.11.2 API Pharma tech Main Business
7.11.3 API Pharma tech Api Drug Development Products, Services and Solutions
7.11.4 API Pharma tech Api Drug Development Revenue (US$ Million) & (2019-2024)
7.11.5 API Pharma tech Recent Developments
7.12 Biocon
7.12.1 Biocon Profile
7.12.2 Biocon Main Business
7.12.3 Biocon Api Drug Development Products, Services and Solutions
7.12.4 Biocon Api Drug Development Revenue (US$ Million) & (2019-2024)
7.12.5 Biocon Recent Developments
8 Industry Chain Analysis
8.1 Api Drug Development Industrial Chain
8.2 Api Drug Development Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Api Drug Development Sales Model
8.5.2 Sales Channel
8.5.3 Api Drug Development Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Almac
Patheon pharma services
Seqens
Malvern Panalytical
CordenPharma
Eurofins CDMO
API Corporation
Wavelength
Sterling
Drug Discovery Alliances
API Pharma tech
Biocon

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂